Mannitol Side Effects
Mannitol's most clinically significant side effects are osmotic diuresis leading to hypovolemia and hypotension, electrolyte disturbances (particularly hyponatremia and hyperkalemia), and acute kidney injury, with these complications being dose-dependent and requiring careful fluid, electrolyte, and renal monitoring. 1, 2
Primary Adverse Effects
Fluid and Electrolyte Disturbances
Mannitol induces potent osmotic diuresis that necessitates volume compensation to prevent hypovolemia and hypotension 3, 1. The most common electrolyte abnormalities include:
- Hyponatremia: Moderate hyponatremia (125-130 mmol/L) occurs in up to 38.7% of patients receiving higher doses (1.5 g/kg), with the incidence being dose-dependent 4
- Hyperkalemia (K+ > 5.0 mmol/L): Observed in approximately 13% of patients at higher doses 4
- Hyperchloremia: Can occur alongside hypernatremia 1
The FDA label explicitly warns that mannitol may obscure and intensify inadequate hydration or hypovolemia, and excessive electrolyte loss can lead to serious imbalances 2. Both fluid balance and sodium/chloride levels require monitoring during administration 1.
Renal Complications
Acute kidney injury represents a serious dose-dependent complication 2, 5. Risk factors include:
- Pre-existing renal disease
- Conditions predisposing to renal failure
- Concomitant nephrotoxic drugs or other diuretics
The FDA contraindication specifically lists well-established anuria due to severe renal disease 2. Avoid combining mannitol with other nephrotoxic agents or diuretics to minimize renal failure risk 2.
Cardiovascular Effects
- Pulmonary congestion and frank pulmonary edema (FDA contraindication) 2
- Progressive heart failure or pulmonary congestion after mannitol initiation (FDA contraindication) 2
- Accumulation may intensify existing or latent congestive heart failure 2
- Hypotension and tachycardia 2
- Angina-like chest pain 2
Central Nervous System Toxicity
Mannitol may increase cerebral blood flow and the risk of postoperative bleeding in neurosurgical patients 2. In pediatric traumatic brain injury, it can worsen intracranial hypertension in children who develop generalized cerebral hyperemia within 24-48 hours post-injury 2.
Osmolality Gap
Higher doses (≥1.0 g/kg) produce osmolality gaps >10 mOsm/kg in 100% of patients, compared to 77.4% with 0.25 g/kg 4. This reflects the osmotic load and correlates with both therapeutic effect and adverse event risk.
Common but Less Severe Effects
The FDA label lists additional frequent adverse reactions 2:
- Cough, hemoptysis, bronchospasm
- Pharyngolaryngeal pain, post-tussive vomiting
- Dryness of mouth, thirst
- Urinary retention, marked diuresis
- Headache, blurred vision
- Nausea, vomiting, rhinitis
- Arm pain, thrombophlebitis, skin necrosis at infusion site
- Convulsions (rare but serious)
- Dizziness, urticaria, fever
Hypersensitivity Reactions
Anaphylactic reactions are rare but documented, including both immediate and delayed-type reactions 6, 7. Symptoms include:
- Respiratory distress, chest tightness
- Hypotension, loss of consciousness
- Urticaria, cyanosis
Delayed anaphylactic shock has been reported after multiple uneventful doses, emphasizing the need for vigilance even in patients who previously tolerated mannitol 6. The FDA contraindicates use in patients with known hypersensitivity 2.
Dose-Dependent Considerations
A prospective randomized trial demonstrated that 1.0 g/kg provides optimal brain relaxation with the fewest adverse effects 4. Higher doses (1.5 g/kg) increased the incidence of moderate hyponatremia (38.7% vs 0-12.9% at lower doses) and hyperkalemia (12.9% vs 0% at lower doses), while lower doses (0.25 g/kg) provided inadequate brain relaxation in 67.8% of patients 4.
Critical Monitoring Requirements
Discontinue mannitol immediately if renal, cardiac, or pulmonary status worsens, or if CNS toxicity develops 2. Essential monitoring includes:
- Cardiovascular status
- Electrolyte levels (sodium, potassium, chloride)
- Fluid balance and urine output
- Renal function
- Osmolality gap when using higher doses